Treatment of Recurrent Bladder Cancer With Dendritic Cells
Phase 2
Completed
- Conditions
- Bladder Cancer
- Interventions
- Biological: Dendritic cellsOther: Standard treatment according to the Clinical protocols
- Registration Number
- NCT04184232
- Brief Summary
Treatment of recurrent bladder cancer with dendritic cells
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 17
Inclusion Criteria
- Histologically confirmed diagnosis of pTa bladder cancer;
- Patient who require repetitive transurethral resection;
- Expression of muc-1/wt-1 by the tumor;
- EGOC 0-3;
Exclusion Criteria
- any medical condition which can be associated with the high risk for the patient;
- pregnancy/lactation;
- chronic infections, including hepatitis B/C, tuberculosis, HIV
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dendritic cells Dendritic cells Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells Control Standard treatment according to the Clinical protocols Patients with the recurrent bladder cancer receiving standard treatment Dendritic cells Standard treatment according to the Clinical protocols Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
- Primary Outcome Measures
Name Time Method Efficacy evaluation 1 year 1 year relapse free survival
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
🇧🇾Minsk, Belarus